CN113521388A - An injectable facial filler composition for skin care and plastic, and its preparation method - Google Patents
An injectable facial filler composition for skin care and plastic, and its preparation method Download PDFInfo
- Publication number
- CN113521388A CN113521388A CN202110871096.9A CN202110871096A CN113521388A CN 113521388 A CN113521388 A CN 113521388A CN 202110871096 A CN202110871096 A CN 202110871096A CN 113521388 A CN113521388 A CN 113521388A
- Authority
- CN
- China
- Prior art keywords
- hyaluronic acid
- dexamethasone
- lidocaine
- mixture
- beta
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 54
- 239000000945 filler Substances 0.000 title claims abstract description 34
- 238000002360 preparation method Methods 0.000 title abstract description 7
- 230000001815 facial effect Effects 0.000 title description 5
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 65
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 65
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 65
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims abstract description 49
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims abstract description 49
- 229960003957 dexamethasone Drugs 0.000 claims abstract description 49
- 229960004194 lidocaine Drugs 0.000 claims abstract description 49
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims abstract description 37
- 238000002156 mixing Methods 0.000 claims abstract description 19
- 238000002347 injection Methods 0.000 claims abstract description 16
- 239000007924 injection Substances 0.000 claims abstract description 16
- 238000003756 stirring Methods 0.000 claims abstract description 4
- 239000002537 cosmetic Substances 0.000 claims description 17
- 238000000034 method Methods 0.000 claims 3
- 150000003384 small molecules Chemical class 0.000 claims 1
- 239000002245 particle Substances 0.000 abstract description 7
- 239000000725 suspension Substances 0.000 abstract description 5
- 230000003796 beauty Effects 0.000 abstract description 2
- 229920002521 macromolecule Polymers 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 239000000463 material Substances 0.000 description 3
- 239000002253 acid Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 101000762366 Homo sapiens Bone morphogenetic protein 2 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 125000000600 disaccharide group Chemical group 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/20—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/12—Phosphorus-containing materials, e.g. apatite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/06—Flowable or injectable implant compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/34—Materials or treatment for tissue regeneration for soft tissue reconstruction
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an injection type face filler composition for beauty and plastic and a preparation method thereof. Comprises 2-3 ml of hyaluronic acid, 0.3-0.6 g of beta-tricalcium phosphate and 0.2-0.4 ml of a mixture of dexamethasone and lidocaine. S1: drawing the mixture of dexamethasone and lidocaine by using a syringe; s2: pouring beta-tricalcium phosphate into a mixture of dexamethasone and lidocaine, and mixing to obtain a colloidal mixture; s3: mixing the colloidal mixture with hyaluronic acid under stirring to obtain face filler. The face filler is filled by mixing hyaluronic acid and beta-tricalcium phosphate particles to form a suspension, and has high compatibility; meanwhile, the face filler can be used for filling different parts of the face after hyaluronic acid is selected and mixed with beta-tricalcium phosphate particles, and the application range is wide.
Description
Technical Field
The invention relates to the technical field of injection type cosmetic materials, in particular to an injection type face filler composition for cosmetic and plastic and a preparation method thereof.
Background
With the improvement of living standard of people, people pay more and more attention to the pursuit of external beauty, and various cosmetic reshaping is generally adopted by people.
Hyaluronic acid, also known as uronic acid and hyaluronic acid, is also called as a azululosidic carbon-based acid in the medical literature, and is a linear polymer polysaccharide composed of disaccharide units (glucuronic acid-N-ethylsulfanylglucose), which is a substance naturally present in tissues and also one of the components of human dermal tissues. The injection of hyaluronic acid is to inject hyaluronic acid into the depressed or abundant part of the skin fold, such as the lip, cheek, nose bridge, chin, scar, etc. by means of filler, so as to reach the effect of eliminating wrinkles and changing appearance immediately. At present, most people have a choice to build the nose for injection of hyaluronic acid, because the nose is not used for operation, does not hurt the skin, has good effect, has good biocompatibility and functions of storing moisture, and can make the skin look very full and elastic. Therefore, hyaluronic acid is a widely appreciated cosmetic product.
However, hyaluronic acid is metabolized in human bodies, belongs to a transient filling material, lasts for about 6 months, and therefore needs to be injected for a long time, so that economic, time and psychological burdens of customers are increased; meanwhile, the hyaluronic acid has insufficient supporting force at the positions of the nose, nasolabial sulcus, chin, temples and the like, so that the forming is not ideal and the effect is influenced.
Disclosure of Invention
The invention aims to overcome the problems that the existing hyaluronic acid facial filler needs to be injected for a long time and has insufficient supporting force at the positions of nose, nasolabial sulcus, chin, temple and the like, and provides an injection type facial filler composition for beautifying and reshaping and a preparation method thereof.
An injection type face filler composition for beautifying and reshaping comprises hyaluronic acid, beta-tricalcium phosphate, dexamethasone and a lidocaine mixture, wherein the hyaluronic acid is 2-3 ml, the beta-tricalcium phosphate is 0.3-0.6 g, and the dexamethasone and the lidocaine mixture is 0.2-0.4 ml.
Further, the hyaluronic acid is 3ml, the beta-tricalcium phosphate is 0.3g, and the mixture of dexamethasone and lidocaine is 0.3 ml.
Further, the mixture of dexamethasone and lidocaine is formed by mixing dexamethasone and lidocaine according to the proportion of 1-5.
Furthermore, the hyaluronic acid is medium-small molecule hyaluronic acid or any one of medium-large molecule hyaluronic acid.
A preparation method of an injection type face filler composition for cosmetic and plastic comprises the following steps:
s1: drawing the mixture of dexamethasone and lidocaine by using a syringe;
s2: pouring beta-tricalcium phosphate into a mixture of dexamethasone and lidocaine, and mixing to obtain a colloidal mixture;
s3: mixing the colloidal mixture with hyaluronic acid under stirring to obtain face filler.
The invention has the beneficial effects that: the face filler is filled by mixing hyaluronic acid and beta-tricalcium phosphate particles to form a suspension, and has high compatibility; meanwhile, the face filler can be used for filling different parts of the face after hyaluronic acid is selected and mixed with beta-tricalcium phosphate particles, and the application range is wide.
Detailed Description
The embodiments of the present invention are described below with reference to specific embodiments, and other advantages and effects of the present invention will be easily understood by those skilled in the art from the disclosure of the present specification. The invention is capable of other and different embodiments and of being practiced or of being carried out in various ways, and its several details are capable of modification in various respects, all without departing from the spirit and scope of the present invention. It is to be noted that the features in the following embodiments and examples may be combined with each other without conflict.
Example 1:
an injection type face filler composition for cosmetic and plastic comprises hyaluronic acid, beta-tricalcium phosphate, dexamethasone and lidocaine, wherein the hyaluronic acid is 2ml, the beta-tricalcium phosphate is 0.3g, and the dexamethasone and lidocaine are 0.2 ml.
The mixture of dexamethasone and lidocaine consists of dexamethasone and lidocaine which are mixed according to the proportion of 1: 1.
The hyaluronic acid is medium-small molecule hyaluronic acid.
The face filler prepared by mixing medium and small molecular hyaluronic acid with beta-tricalcium phosphate, dexamethasone and lidocaine can be used for filling nasolabial sulcus and temples.
Example 2:
an injection type face filler composition for cosmetic and plastic comprises hyaluronic acid, beta-tricalcium phosphate, dexamethasone and lidocaine mixture, wherein the hyaluronic acid is 3ml, the beta-tricalcium phosphate is 0.6g, and the dexamethasone and lidocaine mixture is 0.4 ml.
The mixture of dexamethasone and lidocaine consists of dexamethasone and lidocaine which are mixed according to the proportion of 1: 2.
The hyaluronic acid is medium-small molecule hyaluronic acid.
The face filler prepared by mixing medium and small molecular hyaluronic acid with beta-tricalcium phosphate, dexamethasone and lidocaine can be used for filling nasolabial sulcus and temples.
Example 3:
an injection type face filler composition for cosmetic and plastic comprises hyaluronic acid, beta-tricalcium phosphate, dexamethasone and lidocaine, wherein the hyaluronic acid is 2ml, the beta-tricalcium phosphate is 0.3g, and the dexamethasone and lidocaine are 0.2 ml.
The mixture of dexamethasone and lidocaine consists of dexamethasone and lidocaine which are mixed according to the proportion of 1: 2.
The hyaluronic acid is medium-macromolecule hyaluronic acid.
The face filler prepared by mixing the medium-macromolecule hyaluronic acid with the beta-tricalcium phosphate, the dexamethasone and the lidocaine can be used for filling the nose and the chin.
Example 4:
an injection type face filler composition for cosmetic and plastic comprises hyaluronic acid, beta-tricalcium phosphate, dexamethasone and lidocaine mixture, wherein the hyaluronic acid is 3ml, the beta-tricalcium phosphate is 0.6g, and the dexamethasone and lidocaine mixture is 0.4 ml.
The mixture of dexamethasone and lidocaine consists of dexamethasone and lidocaine which are mixed according to the proportion of 1: 3.
The hyaluronic acid is medium-macromolecule hyaluronic acid.
The face filler prepared by mixing the medium-macromolecule hyaluronic acid with the beta-tricalcium phosphate, the dexamethasone and the lidocaine can be used for filling the nose and the chin.
Example 5:
an injection type face filler composition for cosmetic and plastic comprises hyaluronic acid, beta-tricalcium phosphate, dexamethasone and lidocaine, wherein the hyaluronic acid is 3ml, the beta-tricalcium phosphate is 0.3g, and the dexamethasone and lidocaine are 0.3 ml.
The mixture of dexamethasone and lidocaine consists of dexamethasone and lidocaine which are mixed according to the proportion of 1: 5.
The hyaluronic acid is medium-small molecule hyaluronic acid.
The face filler prepared by mixing medium and small molecular hyaluronic acid with beta-tricalcium phosphate, dexamethasone and lidocaine can be used for filling nasolabial sulcus and temples.
Example 6:
an injection type face filler composition for cosmetic and plastic comprises hyaluronic acid, beta-tricalcium phosphate, dexamethasone and lidocaine, wherein the hyaluronic acid is 3ml, the beta-tricalcium phosphate is 0.3g, and the dexamethasone and lidocaine are 0.3 ml.
The mixture of dexamethasone and lidocaine consists of dexamethasone and lidocaine which are mixed according to the proportion of 1: 4.
The hyaluronic acid is medium-macromolecule hyaluronic acid.
The face filler prepared by mixing the medium-macromolecule hyaluronic acid with the beta-tricalcium phosphate, the dexamethasone and the lidocaine can be used for filling the nose and the chin.
Example 7:
a preparation method of an injection type face filler composition for cosmetic and plastic comprises the following steps:
s1: drawing the mixture of dexamethasone and lidocaine by using a syringe;
s2: pouring beta-tricalcium phosphate into a mixture of dexamethasone and lidocaine, and mixing to obtain a colloidal mixture;
s3: mixing the colloidal mixture with hyaluronic acid under stirring to obtain face filler.
Hyaluronic acid and beta-tricalcium phosphate particles are mixed to form a suspension for filling, and the suspension has good compatibility with surrounding tissues after filling and has no rejection and allergic reaction. The results showed that no significant fibrous capsule formation was seen around the material, and that no BMP2 was expressed. The stable porous crystal balls form a stable bracket for the growth of blood vessels and cells, the stable framework forms a result of lasting curative effect and no displacement, and the beta-tricalcium phosphate and the hyaluronic acid can be safely used as a tissue filler in combination.
As in the following table: the experimental effects of examples 1 to 6 were shown.
The above table shows that the facial filler is filled by mixing hyaluronic acid and beta-tricalcium phosphate particles to form a suspension, and has high compatibility; meanwhile, the face filler can be used for filling different parts of the face after hyaluronic acid is selected and mixed with beta-tricalcium phosphate particles, and the application range is wide.
The above-mentioned embodiments only express the specific embodiments of the present invention, and the description thereof is more specific and detailed, but not construed as limiting the scope of the present invention. It should be noted that, for a person skilled in the art, several variations and modifications can be made without departing from the inventive concept, which falls within the scope of the present invention.
Claims (5)
1. An injectable cosmetic face filler composition characterized by comprising: the hyaluronic acid injection comprises a mixture of hyaluronic acid, beta-tricalcium phosphate, dexamethasone and lidocaine, wherein the hyaluronic acid is 2-3 ml, the beta-tricalcium phosphate is 0.3-0.6 g, and the mixture of dexamethasone and lidocaine is 0.2-0.4 ml.
2. An injectable cosmetic face pack composition according to claim 1, wherein: the hyaluronic acid is 3ml, the beta-tricalcium phosphate is 0.3g, and the mixture of dexamethasone and lidocaine is 0.3 ml.
3. An injectable cosmetic face pack composition according to claim 1, wherein: the mixture of dexamethasone and lidocaine is formed by mixing dexamethasone and lidocaine according to the proportion of 1-5.
4. An injectable cosmetic face pack composition according to claim 1, wherein: the hyaluronic acid is any one of small-molecule hyaluronic acid or medium-molecule hyaluronic acid.
5. The method for preparing the injectable cosmetic/plastic face pack composition according to any one of claims 1 to 4, wherein the method comprises the steps of: the method comprises the following steps:
s1: drawing the mixture of dexamethasone and lidocaine by using a syringe;
s2: pouring beta-tricalcium phosphate into a mixture of dexamethasone and lidocaine, and mixing to obtain a colloidal mixture;
s3: mixing the colloidal mixture with hyaluronic acid under stirring to obtain face filler.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110871096.9A CN113521388A (en) | 2021-07-30 | 2021-07-30 | An injectable facial filler composition for skin care and plastic, and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110871096.9A CN113521388A (en) | 2021-07-30 | 2021-07-30 | An injectable facial filler composition for skin care and plastic, and its preparation method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113521388A true CN113521388A (en) | 2021-10-22 |
Family
ID=78121588
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110871096.9A Pending CN113521388A (en) | 2021-07-30 | 2021-07-30 | An injectable facial filler composition for skin care and plastic, and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113521388A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10351150A1 (en) * | 2003-11-03 | 2005-05-25 | Blue Membranes Gmbh | Method and device for applying a defined amount of a coating material to the surface of a body to be coated |
| WO2014199022A1 (en) * | 2013-06-11 | 2014-12-18 | Tauzin Bénédicte Vincente | Method for cross-linking hyaluronic acid, method for preparing an injectable hydrogel, resulting hydrogel and use thereof |
| CN106999625A (en) * | 2014-11-13 | 2017-08-01 | 莫茨药物股份两合公司 | Dermal augmentation agent based on cross-linking type sodium hyaluronate and carboxymethyl cellulose |
| CN111132705A (en) * | 2017-05-29 | 2020-05-08 | Kh医学技术有限责任公司 | Sterile injection composition containing cross-linked hyaluronic acid and articaine |
| TWM602945U (en) * | 2020-04-24 | 2020-10-21 | 透策生技股份有限公司 | Processing device for accelerating the dispersion of injection-type fillers by means of pressurization |
-
2021
- 2021-07-30 CN CN202110871096.9A patent/CN113521388A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10351150A1 (en) * | 2003-11-03 | 2005-05-25 | Blue Membranes Gmbh | Method and device for applying a defined amount of a coating material to the surface of a body to be coated |
| WO2014199022A1 (en) * | 2013-06-11 | 2014-12-18 | Tauzin Bénédicte Vincente | Method for cross-linking hyaluronic acid, method for preparing an injectable hydrogel, resulting hydrogel and use thereof |
| CN106999625A (en) * | 2014-11-13 | 2017-08-01 | 莫茨药物股份两合公司 | Dermal augmentation agent based on cross-linking type sodium hyaluronate and carboxymethyl cellulose |
| EP3218023A1 (en) * | 2014-11-13 | 2017-09-20 | Merz Pharma GmbH & Co. KGaA | Dermal filler based on crosslinked hyaluronic acid and carboxymethyl cellulose lubricant |
| CN111132705A (en) * | 2017-05-29 | 2020-05-08 | Kh医学技术有限责任公司 | Sterile injection composition containing cross-linked hyaluronic acid and articaine |
| TWM602945U (en) * | 2020-04-24 | 2020-10-21 | 透策生技股份有限公司 | Processing device for accelerating the dispersion of injection-type fillers by means of pressurization |
Non-Patent Citations (1)
| Title |
|---|
| 娄霞等: "对于透明质酸填充注射在医学美容中的临床应用价值和并发症情况进行探究分析", 《中国医疗美容》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210077658A1 (en) | Heat stable hyaluronic acid compositions for dermatological use | |
| US20230277725A1 (en) | Coacervate hyaluronan hydrogels for dermal filler applications | |
| KR102161861B1 (en) | Dermal filler compositions for fine line treatment | |
| US20070196426A1 (en) | Biocompatible crosslinked gel | |
| KR102277655B1 (en) | Method for obtaining an injectable hydrogel based on hyaluronic acid containing lidocaine added in powder form, and an alkaline agent, sterilized with heat | |
| KR20100117563A (en) | Polysaccharide gel formulation | |
| HUE034824T2 (en) | Hyaluronic acid based formulations | |
| CN106492276B (en) | A kind of injectable beauty and shaping material and preparation method thereof | |
| CN110279888A (en) | A kind of injection Ago-Gel agent and preparation method thereof | |
| CN107522881B (en) | Method for preparing single-phase modified sodium hyaluronate gel | |
| CN114642606A (en) | Composition with skin barrier repair function and preparation method and application thereof | |
| CN115068688A (en) | Absorbable face filling material and preparation method and application thereof | |
| CN110292655A (en) | A kind of injection fillers preparation of hydroxyl apatite and preparation method thereof | |
| CN113559322A (en) | Face injection filler for beauty and plastic and preparation method thereof | |
| CN113521388A (en) | An injectable facial filler composition for skin care and plastic, and its preparation method | |
| CN113413330A (en) | Compounding method and compounding preparation of collagen and levorotatory polylactic acid | |
| CN114225117A (en) | A comprehensive facial filler containing crosslinked dextran and its preparation method | |
| CN114404355B (en) | Sodium hyaluronate gel and preparation method and application thereof | |
| Elmahdawi | Overview of hyaluronic acid and its development as dermal fillers gel | |
| US20240091406A1 (en) | Multi-component hydrogel gel and uses of the same | |
| CN117180507A (en) | Recombinant III type collagen composite beautifying injection filling agent and preparation method thereof | |
| RU2724599C1 (en) | Composite material for correction of aesthetic and age-related skin changes and method for production thereof | |
| Holubovska et al. | Creation of cosmeceutical hydrogel mask with plant extract | |
| Bai | Intradermal fillers for skin rejuvenation | |
| JP2021072906A (en) | Coacervate hyaluronan hydrogel for use in dermal filler |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20211022 |